Will Neuralink receive FDA approval for a consumer brain-computer interface before 2029?

Neuralink is still in early clinical trials for its medical BCI device aimed at paralysis patients. Obtaining FDA approval for a consumer product requires completing medical trials first, then pursuing an entirely separate regulatory pathway for consumer devices. The FDA has never approved an invasive BCI for consumer use, and the regulatory, safety, and ethical barriers are enormous. A consumer BCI approval within 3 years is extremely unlikely.

Last updated: Mar 2, 2026

Resolves YES if Neuralink Corp receives FDA Premarket Approval (PMA) or De Novo classification for a brain-computer interface device intended for consumer use (cognitive enhancement, communication augmentation for healthy individuals) before January 1, 2029. Medical-only approvals for paralysis patients do not count.

Source: FDA device approval database and Neuralink official announcements

Expected resolution: February 1, 2029